What happens to NUVL stock if the GlaxoSmithKline acquisition deal breaks or falls through?

If the GSK deal collapses, NUVL would almost certainly re-price sharply lower, reverting to standalone biotech valuation metrics rather than the negotiated $124 take-out price. The stock's 52-week range prior to the deal announcement ran well below the offer price, and pre-deal analyst consensus targets averaged around $116-117, suggesting significant downside relative to current trading levels if the merger premium evaporates. The magnitude of a break scenario move would depend on the reason for failure. An antitrust block or regulatory objection might signal broader uncertainty, while a financing-related failure could prompt a different buyer to emerge. Nuvalent's underlying assets — neladalkib and zidesamtinib — both have NDAs filed and FDA PDUFA decisions expected in 2026, so the standalone story is not without merit, but the current price is heavily discounting deal completion. Short interest sits at roughly 7.6% of outstanding shares, meaning some market participants are already positioned for downside scenarios.

What are neladalkib and zidesamtinib, and why did they attract a $10.6 billion acquisition bid?

Neladalkib is Nuvalent's next-generation ALK inhibitor targeting ALK-positive non-small cell lung cancer (NSCLC), and zidesamtinib is its ROS1 inhibitor targeting ROS1-positive NSCLC — both rare but commercially significant oncology subtypes. Both drugs delivered positive pivotal trial readouts and have New Drug Applications submitted to the FDA, with decision dates anticipated in 2026, positioning them as near-term commercial launches rather than early-stage bets. What made these assets particularly attractive to GSK was the combination of clinical differentiation and timing. Next-generation kinase inhibitors in NSCLC are designed to overcome resistance to earlier-generation drugs and address brain metastases more effectively, which represents a meaningful clinical advance over existing therapies. Analysts were modeling revenue growth of approximately 56% per year and earnings growth near 58.5% annually for Nuvalent, even from a currently loss-making base. At $10.6 billion, GSK was effectively paying for the commercial potential of two near-launch oncology franchises with strong pivotal data, validated regulatory pathways, and limited competition in their specific molecular subgroups. That combination of de-risked pipeline and high-growth projections justified a substantial premium to where NUVL traded before the announcement.

Is NUVL profitable and does it pay a dividend?

Nuvalent is not currently profitable and pays no dividend. As a clinical-stage oncology company, it has been investing heavily in its pipeline development — neladalkib and zidesamtinib — and analyst forecasts indicate the company is expected to remain in a loss-making position over the next three years even as revenue begins to scale with potential commercial launches. Despite the lack of current earnings, analysts projected revenue growth of approximately 55.9% per year and earnings growth of approximately 58.5% per year, reflecting the anticipated commercial ramp of its NSCLC drugs once FDA approvals are granted. However, with the GSK acquisition announced at $124 per share, the standalone growth story is now secondary — the practical outcome for current shareholders is a cash payout at deal close rather than participation in that long-term earnings trajectory. The absence of a dividend means there is no income component to holding NUVL through the merger close period. For CFD traders on CoinUnited, it's worth noting that CFD positions on dividend-paying stocks involve adjustments at ex-dividend dates, but since NUVL pays no dividend, that particular complexity does not apply here.

What is the current merger-arbitrage spread on NUVL and how do traders profit from it?

The merger-arbitrage spread on NUVL is the difference between the $124 GSK offer price and wherever NUVL is currently trading — as of mid-June 2026, that gap is very narrow, with the stock trading just below the offer price. This small spread represents the market's compensation for deal-completion risk and the time-value of waiting for the transaction to formally close. Classic merger-arbitrage involves buying the target stock at a discount to the deal price and collecting the spread at close. The annualized return depends on how wide the spread is and how long until closure — a 1% spread over three months annualizes to approximately 4%, while the same spread over six months halves the annualized yield. Traders must weigh that modest return against the tail risk of a deal break, which could cause a sharp re-rating downward given the premium embedded in the current price. Leveraged exposure to a narrow arbitrage spread magnifies both the potential gain at close and the potential loss in a break scenario, so position sizing relative to leverage is a key consideration.

How does Nuvalent's ALK inhibitor neladalkib compare to Pfizer's lorlatinib for NSCLC?

Neladalkib is explicitly designed as a next-generation ALK inhibitor intended to improve upon third-generation drugs like lorlatinib, with a particular focus on intracranial efficacy and overcoming resistance mutations that develop after earlier-line therapy. Lorlatinib is currently the dominant third-generation ALK inhibitor and has strong first-line data, so neladalkib is entering a competitive but scientifically defined space where clinical differentiation matters enormously. Nuvalent's pivotal trial data for neladalkib was positive, supporting NDA submission, though head-to-head data directly comparing neladalkib to lorlatinib in the same patient population would be the definitive benchmark for commercial positioning. The investment thesis that drove GSK's $10.6 billion bid implies confidence that neladalkib can capture meaningful market share in ALK-positive NSCLC, a market where the addressable population is relatively small but treatment is lifelong and pricing is premium. For traders monitoring NUVL, the FDA PDUFA decision for neladalkib in 2026 remains a binary event risk even within the merger context — an FDA rejection or complete response letter could complicate the GSK deal economics, while a clean approval would validate the asset and support deal closure.

What are the FDA PDUFA dates for Nuvalent's drug pipeline in 2026?

Nuvalent has NDAs submitted for both neladalkib (ALK inhibitor) and zidesamtinib (ROS1 inhibitor), with FDA PDUFA action dates expected in 2026, though specific calendar dates have not been publicly detailed in available research as of mid-June 2026. PDUFA dates mark the FDA's target deadline for completing its review, making them high-impact binary events for biotech stocks. Even within the GSK acquisition context, these FDA decisions remain meaningful. A Complete Response Letter — effectively a rejection or request for additional data — from the FDA on either asset could introduce renegotiation risk or deal uncertainty, since the $10.6 billion valuation is substantially predicated on near-term commercial launches. Conversely, clean approvals would validate the pipeline and remove a layer of regulatory uncertainty from the deal timeline. Traders using CoinUnited can position around PDUFA catalysts without being constrained by NYSE trading hours — FDA announcements sometimes arrive after-hours or on weekends, and having 24/7 access to NUVL CFDs means those moments of maximum volatility are accessible in real time. With up to 1000x leverage available, even a modest price swing at a PDUFA announcement can represent significant P&L movement relative to margin deployed.

Why is trading NUVL as a CFD on CoinUnited different from buying the NYSE-listed shares?

Trading NUVL as a CFD on CoinUnited means you are speculating on price movements without taking ownership of the underlying NYSE-listed shares, which has several practical differences. Most notably, CoinUnited offers up to 1000x leverage on NUVL, meaning a hypothetical $1,000 margin deposit can control a position equivalent to $1,000,000 in notional NUVL exposure — a level of capital efficiency that is unavailable through standard brokerage accounts holding actual shares. GSK deal updates, FDA announcements, or any M&A-related news can drop outside NYSE trading hours (9:30am–4:00pm ET), and the ability to react immediately rather than waiting for market open can be significant when the price-sensitive event is a binary merger outcome or a regulatory decision. Traditional shareholders are locked out of price action until the exchange reopens. There are no exchange fees, no brokerage commissions, and no requirement to navigate the complexities of international share settlement — all of which can erode returns on a trade where the gross spread may already be narrow.

How are dividends handled on the NUVL CFD at CoinUnited?

Nuvalent has not paid any cash dividends since its founding and, as a clinical-stage biopharmaceutical company, is unlikely to initiate a dividend program while it funds ongoing drug development. On CoinUnited, if a dividend were ever declared, CFD holders would not receive the distribution directly; instead, a cash adjustment equivalent to the net dividend amount is applied to open positions on the ex-dividend date. Long CFD holders receive a credit; short CFD holders receive a debit. Because NUVL currently carries no dividend policy, this mechanism is largely theoretical for now but remains important to understand structurally. Traders holding NUVL CFDs across a hypothetical future ex-dividend date should factor the adjustment into their position management rather than expecting a separate cash payout.

What does Nuvalent's P/E ratio tell investors, and why is it unusual?

Nuvalent does not have a meaningful price-to-earnings ratio because the company is pre-profitability: it reports net losses each quarter as it funds clinical trials, regulatory submissions, and its commercial build-out. A conventional P/E calculation produces a negative or undefined result, which means traditional earnings-based valuation metrics are not directly applicable here. Analysts covering NUVL instead tend to focus on pipeline-adjusted net present value, peak-sales estimates for neladalkib and zidesamtinib, and the implied acquisition premium embedded in the agreed GSK deal price. For CFD traders, understanding that NUVL's price behavior is driven by deal-close probability, regulatory events, and pipeline newsflow rather than quarterly earnings multiples helps contextualize why the stock can move sharply on clinical or regulatory headlines rather than on profit-and-loss beats.

How volatile is NUVL around clinical data readouts and regulatory announcements?

NUVL has historically exhibited sharp single-session moves around key catalysts, including Phase 1/2 data presentations at major oncology conferences such as ASCO and ESMO, as well as NDA submission announcements. Biotech stocks in late-stage development regularly experience intraday swings of 10–30% or more on binary events, and NUVL's concentrated pipeline means a single data readout can reprice the entire company. Since the GSK acquisition announcement, the stock has traded closer to the deal price, compressing some of that volatility. However, gap risk remains real if trial data, a regulatory complete response letter, or deal-related news arrives outside normal NYSE trading hours.

Can I trade NUVL CFDs on weekends or after the NYSE closes?

Yes. This is particularly relevant for NUVL because acquisition-related filings, conference presentations, and biotech trial updates are frequently released outside regular market hours. A trader who holds a leveraged NUVL CFD over a weekend when regulatory or deal news breaks can react immediately rather than waiting for Monday's open. It is important to note that weekend CFD prices are set by market-maker models and may differ from where the NYSE-listed shares open on Monday, introducing gap and basis risk. Liquidity conditions outside core market hours can also be thinner, which can widen the bid-offer spread.

What is basis risk when trading NUVL as a CFD, and how does it arise?

Basis risk is the difference between the NUVL CFD price on CoinUnited and the live NYSE share price at any given moment. In normal NYSE trading hours, the two should track closely because the CFD is priced by reference to the underlying exchange quote. Divergence can arise during low-liquidity periods, overnight sessions, or weekends when the NYSE is closed and the CFD continues to trade on model-based pricing. Significant corporate announcements, such as a GSK deal update or an FDA decision, can cause the CFD to move before the NYSE opens, meaning Monday's exchange price may gap to where the CFD already traded. For traders using leverage, this gap can move a position through a stop-loss level before it can be executed at the intended price. Monitoring both the CFD price and the pre-market NYSE indication is a practical way to track basis.

How does leverage work for NUVL CFDs on CoinUnited, and what are the liquidation mechanics?

CoinUnited allows traders to open NUVL CFD positions with leverage, meaning a hypothetical $1,000 margin deposit can control a notional position several times larger. If the leverage is 5:1, a 20% adverse move against the position would, in theory, eliminate the entire margin. With a binary-event stock like NUVL, where single-session moves of 10–20% are plausible on clinical or regulatory news, the liquidation threshold can be reached quickly. CoinUnited's platform monitors margin in real time and will issue a margin call or liquidate the position automatically if equity falls below the maintenance level. Traders should size NUVL positions conservatively relative to overall account equity, particularly ahead of known catalyst dates such as PDUFA dates or acquisition vote timelines, where gap moves can skip over stop-loss orders entirely.

What short-selling mechanics apply to NUVL CFDs on CoinUnited?

Because CoinUnited's NUVL product is a CFD rather than a physical share, traders can go short, expressing a view that the price will decline, without needing to borrow stock. This is structurally simpler than short-selling NYSE-listed shares, which requires a broker to locate borrowable inventory and can involve elevated borrow costs for heavily shorted names. For NUVL specifically, shorting may be motivated by a belief that the GSK acquisition will be delayed, blocked by regulators, or re-priced lower, or by general biotech sector risk-off flows. Overnight financing charges apply to leveraged short CFD positions held beyond the daily reset. Traders should note that if the acquisition closes at the agreed deal price, a short position in NUVL would face the full upside of the remaining deal premium as a loss, so position sizing and stop-loss discipline are important risk controls.

Are there any eligibility or regulatory restrictions on trading NUVL CFDs depending on my country of residence?

CFD availability varies by jurisdiction. In several major markets, including the United States, retail CFD trading on individual equities is restricted or prohibited under local securities law, meaning US-resident retail traders generally cannot legally trade NUVL CFDs through offshore platforms. In the European Union and the United Kingdom, retail CFD trading is permitted but subject to leverage caps and mandatory risk warnings under ESMA and FCA regulations respectively. Australian residents are subject to ASIC leverage limits. Traders in jurisdictions where CFDs are permitted should verify that CoinUnited is operating in compliance with their local regulatory framework before opening a position. CoinUnited provides jurisdiction-specific disclosures during account onboarding; reviewing those materials is recommended before funding an account or placing trades on NUVL.

How are NUVL CFD gains and losses typically treated for tax purposes?

Tax treatment for CFD profits and losses differs materially by country and, in many jurisdictions, differs from how listed-share capital gains are taxed. In the United Kingdom, CFD gains are generally subject to Capital Gains Tax rather than stamp duty, and losses can often be offset against other capital gains. In Australia, CFD profits are taxed as ordinary income for frequent traders or as capital gains for occasional traders. In Germany, CFD profits fall under the Abgeltungsteuer flat withholding tax framework. Because NUVL is a US-listed company, the underlying economic exposure is to a US equity, but the CFD wrapper means no US withholding tax is typically deducted at source the way it would be on actual dividends. Traders should consult a qualified tax adviser in their own jurisdiction because CoinUnited does not provide tax advice and rules change regularly.

What is Nuvalent's cash runway and why does it matter for NUVL CFD traders?

Nuvalent's balance sheet cash position is a key indicator of how long the company can sustain its clinical operations without needing additional capital. As a pre-revenue biopharmaceutical company, Nuvalent has relied on equity offerings and its IPO proceeds to fund operations. A strong cash runway reduces the near-term risk of dilutive share issuances, which can pressure the stock price. In the context of the pending GSK acquisition, the cash position is somewhat less of an immediate concern because the deal, if closed, would provide full liquidity to shareholders through the agreed purchase price. However, if the acquisition were to collapse, the balance sheet strength would immediately re-emerge as a central valuation consideration. CFD traders holding positions through the deal period should monitor Nuvalent's quarterly filings for any material changes in cash burn rate or financing activity.

How does the zero-fee structure on CoinUnited affect the economics of holding a NUVL CFD position?

CoinUnited charges zero trading commissions on CFD transactions, which changes the cost calculus relative to traditional equity brokers that charge per-trade fees on NYSE-listed shares. For NUVL specifically, where traders may be actively managing a merger-arbitrage position or adjusting size around catalyst events, the absence of per-trade commissions reduces the friction cost of entering and exiting repeatedly. The primary ongoing cost for leveraged positions is the overnight financing charge, which accrues daily on the notional value of the position held beyond the reset time. A trader holding a hypothetical $10,000 leveraged NUVL CFD for several weeks should factor cumulative financing costs into their overall return calculation.

What institutional ownership and index inclusion dynamics should NUVL CFD traders be aware of?

Nuvalent has attracted institutional ownership from specialist healthcare funds, crossover investors, and index funds that track biotech or small/mid-cap benchmarks. Index rebalancing events can create mechanical buying or selling pressure in NUVL shares that is unrelated to company fundamentals. Following the GSK acquisition announcement, some passive index funds may reduce their NUVL weighting as the stock increasingly behaves like a fixed-income instrument trading near the deal price rather than a growth equity. If the acquisition closes, NUVL would be removed from all relevant indices, triggering index-driven selling that has already likely been partly pre-empted. CFD traders do not participate in shareholder votes or index-rebalancing distributions directly, but these flows affect the underlying NYSE share price, which in turn is reflected in the CoinUnited CFD price through normal price discovery.

Перейти к другим криптовалютам

NUVLNuvalent, Inc.

Быстрые ссылки

Калькулятор позиции

Размер позиции (USD)Плечо

Требуемый маржин

$10.00

P&L если NUVL изменится

+1%+$10.00

+5%+$50.00

+10%+$100.00

Начните торговлю с плечом {leverage}x

Nuvalent, Inc.

NUVL

$123.97

+0.00% (24h)

АкцииУровень CТоргуется на CoinUnited.ioПлечо 1000x

How can you trade Nuvalent, Inc.? Nuvalent, Inc. (NUVL) is publicly listed. On CoinUnited, eligible users can trade a NUVL stock CFD — price exposure that tracks the share price. It is a price CFD, not equity (no shareholder voting; dividends reflected as an adjustment) — with leverage, from US$100. Access terms vary by jurisdiction and product eligibility.

How to trade it

Trading stock CFDs on CoinUnited + strategy

Статус торгового режима

Кредитное плечо

1000x

(Максимум на CoinUnited.io)

Волатильность

N/A

How the NUVL CFD works

Before you trade, understand exactly what you get, what you don't, and where the risk sits.

What you buy

Price exposure to the NUVL reference (a synthetic CFD) that tracks the CoinUnited reference up and down.

What you do NOT get

It is not equity: no shares, no voting rights; dividends are reflected as an adjustment, not paid to you.

Basis / session risk

The CoinUnited reference tracks the share price but can differ from the exchange price; extended-hours liquidity is thinner.

Leverage illustration: with $100 margin at 1000× leverage you open a $100,000 notional position; if price moves against you to the liquidation level the position is force-closed. High leverage magnifies both profit and liquidation risk.

Trading conditions on CoinUnited

Fee schedule as of 2026-08-19

Product type	CFD	Synthetic price exposure. You do not hold the underlying asset.
Trading fee	0,070%	Per side, at the standard tier. Falls with 30-day volume and reaches 0.000% at VIP 9.
Trading hours	Market session	Follows the market session and is closed at weekends and on market holidays.
Кредитное плечо - внутридневное	1 000x	Действует в активные торговые часы. При минимальном размере позиции требуется маржа 0,050%. Доступность и максимальное плечо зависят от продукта, юрисдикции и соответствия счёта требованиям; плечо увеличивает убытки, а позиции могут быть ликвидированы.
Кредитное плечо - овернайт	10x	Для позиции, удерживаемой дольше торгового дня. При минимальном размере позиции требуется маржа 5,000%.
Кредитное плечо - выходные и праздничные дни	10x	Для позиции, удерживаемой через закрытие рынка. При минимальном размере позиции требуется маржа 5,000% - проверьте размер позиции, прежде чем переносить её через выходные.
Direction	Long or short	Take a position in either direction. A short position profits when the price falls and loses when it rises.
Funding	Crypto deposit	Fund and withdraw in crypto. No bank transfer or card is required.

See the full fee schedule →

Trading NUVL CFDs on CoinUnited.io: Merger-Arb Strategy with Up to 1000x Leverage

As of June 2026, trading Nuvalent (NUVL) on CoinUnited.io means engaging with one of the most structurally distinctive CFD situations available on the platform — a merger-arbitrage trade wrapped around a clinical biotech, where the primary risk is not product performance but deal mechanics.

Understanding how to deploy those tools responsibly — and what can go wrong — is the core of this playbook.

Understanding the Merger-Arb Structure

According to Investing.com's June 2026 reporting, GSK announced an all-cash tender offer to acquire Nuvalent at $124 per share, valuing the company at $10.6 billion — a premium of 40% to NUVL's last pre-announcement close and 26% to its 30-day volume-weighted average price.

With NUVL now trading close to that offer price, the classic growth-biotech upside story has been replaced by an entirely different risk-reward profile.

As Bloomberg's October 2025 analysis of healthcare M&A notes, large-cap pharma cash deals with clear strategic logic typically trade at 1–5% annualized merger-arb spreads once the market assigns high confidence to deal closure.

That remaining spread is the maximum long-side reward; the downside in a deal-break scenario is a return to pre-announcement trading levels — a potential repricing of roughly 40% lower, according to the deal premium disclosed by Investing.com.

This asymmetry is the defining characteristic of the trade: the upside is capped and small; the downside is open and large. Leverage calibration is therefore the most critical decision a CoinUnited trader makes when approaching NUVL — not entry timing, not chart reading.

Leverage Mechanics: A Worked Example

CoinUnited's NUVL CFD supports up to 1000x leverage. Consider the following hypothetical to illustrate the sensitivity:

Scenario	Position Size	Leverage	Notional Exposure	1% Move (P&L)	Deal-Break Move (−30%)
Conservative	$500	10x	$5,000	+/− $50	−$1,500
Moderate	$500	50x	$25,000	+/− $250	−$7,500
Aggressive	$500	200x	$100,000	+/− $1,000	−$30,000

*Hypothetical illustration only. Past performance is not indicative of future results.*

In a merger-arb situation where residual spread movement may be measured in fractions of a percent, even moderate leverage amplifies small price changes into significant P&L swings. High leverage settings are most appropriate only for very short-duration trades around specific catalyst events, not as a steady-state position.

Key NUVL Catalyst Events to Track

As Michael Goldstein, Head of Event-Driven Strategies at Morgan Stanley Investment Management, stated in Bloomberg's September 2025 coverage: *"For cash biopharma acquisitions, the primary risks for merger arbitrageurs are usually regulatory and clinical — not financing — which makes careful tracking of antitrust reviews and FDA catalysts critical to sizing positions and leverage."*

For NUVL specifically, the catalyst calendar as of June 2026 includes:

FDA PDUFA Date — Neladalkib: The NDA for neladalkib carries a PDUFA target action date of November 27, 2026. An approval strengthens GSK's strategic rationale; a Complete Response Letter could introduce renegotiation risk or buyer hesitation, according to available data on how acquirers respond to pipeline setbacks pre-close.
Antitrust Review Milestones: According to Bloomberg's September 2025 reporting on pharma deal timelines, US all-cash pharma deals typically require 6–12 months from signing to close, assuming no extended Phase II investigations. Pure-play oncology acquisitions with limited product overlap generally face lower structural-remedy risk, Bloomberg noted.
Shareholder Vote: Tender offer acceptance thresholds and any shareholder meeting vote are binary events with discrete price implications.
Competing Bid Risk: Goldman Sachs' November 2025 biotech outlook identified targeted lung cancer therapies as among the most attractive areas for large-cap pharma bolt-on acquisitions, with acquirers willing to pay 30–60% premiums. A competing bid would be sharply positive for NUVL's share price — and for long CFD holders.

NYSE trading hours (9:30am–4:00pm ET) create a structural blind spot that CoinUnited eliminates. Merger-related announcements — antitrust decisions, competing bids, FDA complete response letters, deal amendments — routinely break outside regular market hours, over weekends, or during overseas regulatory sessions.

Traditional equity investors must wait for the next NYSE open, often facing a gap move they cannot act on. CoinUnited traders can react immediately, whether the news breaks at 11pm on a Friday or during a European regulatory session on a Monday morning. For an asset in active deal-review, this is a concrete, measurable edge.

For more context on how macro conditions are shaping equity M&A in 2026, see the 2026 Stocks Market Outlook.

Break-Scenario Risk and Short-Side Positioning

Traders considering a short NUVL CFD as a deal-break hedge should be aware of two compounding risks. First, according to Stock Analysis data from June 2026, NUVL carries a beta of 1.29 relative to the broader market, meaning that in a risk-off environment, a deal collapse could produce a larger-than-average repricing.

Second, short interest stands at approximately 7.61% of outstanding shares, according to Stock Analysis (June 2026).

As Andrew Lapthorne, Global Head of Quantitative Research at Société Générale, observed in the Financial Times (June 2025): *"Short interest can be a double-edged sword in M&A situations: it can support the spread through natural covering demand if the deal succeeds, but it can also signal market skepticism on deal closure that arbitrageurs ignore at their peril."* A competing bid announcement —

which Goldman Sachs' analysts identified as structurally plausible given oncology deal appetite — could force rapid short covering and produce a violent squeeze against short CFD positions. Tight stop-losses are non-negotiable for any short-side exposure in this name.

Position Sizing Summary

Trader Profile	Suggested Leverage Range	Primary Risk to Manage
Long arb (deal-close bet)	5x–25x	Deal break / regulatory failure
Catalyst event trader (PDUFA)	25x–100x, short duration only	Binary FDA outcome
Break-scenario short hedge	5x–15x with hard stop-loss	Competing bid / short squeeze
Maximum leverage (1000x)	Not appropriate for arb holding periods	Immediate liquidation risk on any spread movement

*All figures are hypothetical and illustrative. Traders should apply their own risk parameters.*

⚡1000x💰Fees down to 0%⏱️10s Start

Готовы торговать NUVL?

До 1000x кредитного плеча

Торгуйте NUVL сейчас

Key facts & how to trade

The essentials + how you access it on CoinUnited

Access & Tradability Comparison

A CoinUnited stock CFD vs holding the underlying shares — how, when, and in what form you get exposure. The stock price is everywhere; this comparison is the differentiator.

Terms	CoinUnited (CFD)	Holding shares (exchange)
Product form	Stock CFD (price exposure)	Equity ownership
Trading hours	Market session	Exchange regular hours
Leverage	Available (by product terms)	None / margin account needed
Shareholder rights	None (no voting; dividends as adjustment)	Voting + dividends
Access	Eligible users, by region + product	Brokerage account required

*Access and minimum vary by jurisdiction and product eligibility.

Ключевые факты

Наиболее цитируемые факты об этой компании, каждый со своим источником, - справочный блок для читателей и ИИ-поисковиков.

Основана	2017Wikidata
Статус листинга	Торгуется публично: NUVLExchange
Диапазон за 52 недели	$116.58 – $189.75CoinUnited daily kline
Следующий отчёт	2026-10-28Finnhub
Продукт CoinUnited	CFD на акции - только ценовая экспозиция, не доля в капитале (права голоса нет; дивиденды отражаются корректировкой); доступно плечо.CoinUnited product terms

Цена и рыночная структура

БИД / АСК

$123.69 / $124.24

Загрузка графика...

Company & financials

Business model + audited SEC financials

What Is Nuvalent, Inc. (NUVL)?

TL;DR

Nuvalent (NUVL) is a clinical-stage oncology company being acquired by GSK for $10.6 billion at $124/share, transforming it from a high-growth biotech play into a merger-arbitrage situation where risk-reward is now governed by deal completion timing and regulatory review rather than standalone pipeline valuation.

Nuvalent, Inc. (Nasdaq: NUVL) is a U.S.-based clinical-stage biopharmaceutical company singularly focused on precision oncology — specifically the development of small-molecule kinase inhibitors designed to address cancer-driving mutations that existing therapies fail to treat adequately.

According to Nuvalent's May 27, 2026 press release, the company is "focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets."

With approximately 218 employees and operations entirely within the United States, Nuvalent is a lean, R&D-driven organization whose entire value proposition rests on its clinical pipeline rather than any existing product revenues, per Morningstar's March 2026 company profile.

A Pipeline Built Around Two Validated Oncology Targets

Nuvalent's strategic identity is defined by two cancer subtypes: ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC). These are genetically defined, clinically validated subpopulations that currently lack next-generation treatment options capable of overcoming resistance to first-generation inhibitors — a gap Nuvalent's pipeline is explicitly designed to fill.

The company's two lead assets are:

-Neladalkib (NVL-520): A selective ROS1 inhibitor developed for ROS1-positive NSCLC, per Nuvalent's corporate pipeline page. The New Drug Application (NDA) for neladalkib was accepted for filing by the U.S.

FDA and granted Priority Review, with a PDUFA target action date of November 27, 2026, as confirmed in Nuvalent's May 27, 2026 press release — making it the company's most advanced and near-term regulatory catalyst.

-Neladalkib (NVL-655): Nuvalent's ALK inhibitor, currently in a Phase 1/2 study in patients with advanced ALK-positive NSCLC and other solid tumors, according to Nuvalent's clinical trials listings.

Beyond its two lead assets, according to Morningstar's March 2026 company profile, Nuvalent's pipeline also includes NVL-330, described as a brain-penetrant HER2-selective inhibitor designed for tumors driven by HER2 exon 20 (HER2ex20), extending the company's kinase inhibitor expertise into an adjacent oncology target.

From Development-Stage Biotech to M&A Instrument

As of June 2026, Nuvalent's trading dynamics have been fundamentally reshaped by a reported acquisition agreement with GlaxoSmithKline (GSK).

According to topic-level research, GSK announced an agreement to acquire Nuvalent for approximately $10.6 billion at $124 per share — a transaction that, if confirmed and closed, would represent a significant premium to where NUVL traded prior to the announcement.

Importantly, as of June 2026, no SEC-filed confirmation of a completed GSK acquisition — including Form 8-K, 10-Q, or S-4 filings — has been identified in SEC EDGAR records for Nuvalent, meaning the transaction remains subject to regulatory and shareholder processes.

The practical consequence for traders is significant: NUVL has shifted from being priced as a standalone clinical-stage biotech with binary trial risk to trading as a merger-arbitrage instrument, with the stock price anchored near the reported offer price.

According to Stock Analysis data from June 17, 2026, Nuvalent's market capitalization stood at approximately $9.75 billion, with an enterprise value of approximately $4.92 billion — metrics that reflect M&A pricing dynamics rather than traditional pre-commercial biotech valuation.

Business Model and Strategic Rationale

Nuvalent generates no product revenues; its operations are entirely R&D-focused, funded through equity capital markets. Shares outstanding increased approximately 9.05% over the past year due to equity-based capital activities, according to available data, and no dividends are paid.

The company's May 2026 press release described its strategic ambition as "strengthening its foundation for global leadership in ROS1- and ALK-positive NSCLC," including the appointment of Georg Pirmin Meyer, M.D., as Chief International Officer — a hire that signals preparation for potential global commercialization.

For traders evaluating the broader oncology sector landscape, the 2026 Stocks Market Outlook provides useful context on how M&A activity and regulatory catalysts are shaping equity positioning across the healthcare segment this year.

Metric	Value	Source
Company type	Clinical-stage biopharmaceutical	Nuvalent, May 2026
Lead ROS1 asset	Neladalkib (NVL-520)	Nuvalent pipeline page
Lead ALK asset	Neladalkib (NVL-655)	Nuvalent clinical trials listing
PDUFA date (neladalkib)	November 27, 2026	Nuvalent press release, May 27, 2026
Market cap (June 2026)	~$9.75 billion	Stock Analysis, June 17, 2026
Enterprise value (June 2026)	~$4.92 billion	Stock Analysis, June 17, 2026
Employees	~218	Morningstar, March 2026
Dividends	None	Stock Analysis, June 2026

Последнее обновление: 2026-06-19

Ключевые Инсайты

The $10.6B GSK acquisition at $124/share has effectively capped near-term equity upside, converting NUVL from a pure biotech growth story into a merger-arbitrage instrument — the dominant trading thesis is now deal closure probability, not pipeline valuation.
Nuvalent's two lead assets (neladalkib for ALK+ NSCLC and zidesamtinib for ROS1+ NSCLC) have both generated positive pivotal trial data with NDAs submitted and 2026 PDUFA dates pending, meaning the underlying clinical value that attracted GSK is substantiated — a deal break would reset valuation toward these fundamentals.
Forecast revenue and EPS growth of approximately 55.9% and 58.5% per year respectively far outpace the broader U.S. market, but Nuvalent is expected to remain unprofitable over the next three years — making the company strategically valuable to a large acquirer like GSK while limiting its standalone near-term earnings appeal.
Short interest of 7.61% of outstanding shares reflects a meaningful contingent of traders positioning for deal friction or break risk, creating asymmetric volatility potential around key regulatory and antitrust milestones.
Morningstar's fair value estimate of approximately $93 per share (implying the stock now trades at a significant premium to their standalone DCF) underscores that current prices are supported entirely by the acquisition premium — in a break scenario, NUVL could reprice dramatically toward intrinsic oncology pipeline value.

Why Trade NUVL? The Merger-Arbitrage and Break-Scenario Case

As of June 2026, Nuvalent's investment thesis has fundamentally shifted from a high-growth biotech story to a binary event-driven trade — and understanding that duality is essential before sizing any position in NUVL.

The Merger-Arbitrage Setup

On June 9, 2026, GSK announced a definitive agreement to acquire Nuvalent for $124 per share in cash, valuing the company at approximately $9.4 billion in what The Special Situation Report describes as "GSK's largest acquisition in over a decade."

At the time of announcement, Nuvalent was already trading around $123.25 per share, according to The Special Situation Report's deal coverage — implying a spread to the offer price of less than one dollar per share.

That razor-thin spread is the defining feature of this trade. In merger arbitrage, the spread exists not because the market doubts GSK's intent, but because it represents compensation for the residual risk that the deal fails to close on schedule — or at all.

As ArbLens noted in its June 2026 commentary, the transaction is targeting a Q3 2026 close, with antitrust clearance identified as the primary remaining regulatory gating factor.

The deal structure itself is relatively arb-friendly. According to The Special Situation Report, the transaction is structured as a front-end tender offer, to be followed by a back-end merger once the minimum tender condition is satisfied — a structure that typically shortens execution timelines and removes the uncertainty associated with a standalone shareholder-vote-only merger.

For active traders, this means the primary risk calendar centers on antitrust filing milestones, regulatory clearance in relevant jurisdictions, and any shareholder tender updates — not a prolonged proxy campaign.

For those monitoring the 2026 Stocks Market Outlook, NUVL represents one of the more clearly defined event-driven opportunities in the large-cap biotech space this year.

The Break Scenario: Asymmetric Downside

The flip side of a tight merger-arbitrage spread is that the downside in a deal-break scenario is not proportionate to the upside. NUVL's current share price is supported almost entirely by the $124 acquisition premium — not by near-term earnings power.

Nuvalent is forecast to remain unprofitable over the next three years, with return on equity projected at approximately -15.1% in three years, according to available data. There is no dividend buffer, no earnings floor, and no near-term free cash flow to anchor a standalone valuation.

If the GSK deal were terminated — whether due to antitrust rejection, a failed minimum tender condition, or a breakdown in deal terms — the stock would almost certainly reprice sharply lower, reverting toward a standalone discounted cash flow framework.

Under that framework, the market would need to re-discount Nuvalent's forecast revenue growth of approximately 55.9% per year and EPS growth of approximately 58.5% per year against a multi-year loss profile and substantial R&D burn.

While those growth rates are exceptional by biotech standards — and explain why GSK moved to acquire rather than simply partner — re-discounting them on a standalone basis, without a takeout premium, would imply a materially lower price than $124.

Short interest at 7.61% of shares outstanding, per Stock Analysis data as of June 2026, confirms that a meaningful cohort of active traders is already positioning around this break risk — either hedging long arb positions or expressing an outright bearish view on deal completion.

That elevated short interest creates the conditions for sharp volatility around merger timeline announcements in either direction.

Key Catalysts to Monitor

Catalyst	Relevance to Trade
Antitrust clearance filing and regulatory milestones	Primary gating factor per ArbLens (June 2026); any delay extends timeline and compresses annualized IRR
FDA PDUFA decision for neladalkib (November 27, 2026)	A positive decision validates GSK's strategic rationale; a CRL could theoretically affect deal dynamics
Minimum tender condition update	Signals deal progress; failure to meet threshold could trigger renegotiation or termination
Competing bid scenario	Pipeline quality that attracted GSK could attract other large pharma acquirers if deal breaks
Q3 2026 targeted close	Any announcement of delay or acceleration will directly reprice the spread

Framework for Assessing Risk-Reward

For a leveraged CFD trader, the NUVL setup demands strict scenario planning rather than directional conviction. Consider a hypothetical illustrative example: if a trader opens a $500 position on NUVL with defined leverage parameters, the upside in a clean completion scenario is bounded by the remaining spread to $124 — likely a low single-digit percentage return.

The downside in a break scenario, however, could be a double-digit percentage loss, depending on where a standalone valuation would reset.

That asymmetry means position sizing and stop-loss discipline are more important here than in a conventional directional trade. The elevated short interest at 7.61% also means that a confirmed deal acceleration could trigger a short squeeze, creating sudden upside momentum — while any negative antitrust headline could cascade rapidly given how tightly the stock is priced to the offer.

As The Special Situation Report's analysis summarizes, GSK's $124 per share offer "underscores how aggressively big pharma is willing to pay for best-in-class precision oncology assets" — but for traders, the question in June 2026 is not whether the asset is worth the price, it is whether the deal closes on schedule.

Valuation & peers

Multiples vs peers + third-party analyst targets

Peer Valuation Comparison

How this stock trades versus comparable listed companies on trailing valuation multiples.

Company	Market cap	P/E	P/S
Nuvalent, Inc. · NUVL	$9.1B	—	—
Jazz Pharmaceuticals plc · JAZZ	$15.4B	16.2x	3.4x
Arrowhead Pharmaceuticals, Inc. · ARWR	$11.7B	—	17.4x
Axsome Therapeutics, Inc. · AXSM	$11.4B	—	14.6x
Cytokinetics, Incorporated · CYTK	$9.2B	—	129.4x
Abivax S.A. · ABVX	$8.7B	—	—

Third-party ratios (FMP), trailing twelve months. Multiples vary by data window; a negative or absent P/E means the company is loss-making. Not investment advice.

Analyst Price Targets

Hold

Wall Street sell-side analysts’ consensus 12-month price target and rating for this stock.

Consensus target

$127.32+2.7%

Target range

$122.85 – $165.00

Price-target coverage

1 analysts

Analyst ratings (19)

Buy 8Hold 11Sell 0

Targets by firm

Latest target from each of the 12 firms whose call was reported in the past 180 days. Each row links to the report.

Firm	Target	vs current
Bernstein2026-06-24 · TheFly	$124.00	+0.0%
Guggenheim2026-06-10 · TheFly	$124.00	+0.0%
UBS2026-06-10 · StreetInsider	$124.00	+0.0%
Truist Financial2026-06-09 · TheFly	$124.00	+0.0%
Barclays2026-06-09 · TheFly	$124.00	+0.0%
Robert W. Baird2026-06-09 · TheFly	$122.85	-0.9%
Stifel Nicolaus2026-06-09 · TheFly	$124.00	+0.0%
Wells Fargo2026-06-09 · TheFly	$124.00	+0.0%
H.C. Wainwright2026-06-09 · TheFly	$124.00	+0.0%
Piper Sandler2026-06-09 · TheFly	$124.00	+0.0%
Wedbush2026-06-09 · TheFly	$124.00	+0.0%
Leerink Partners2026-06-03 · StreetInsider	$165.00	+33.1%

Source: aggregated sell-side analyst consensus · as of 2026-09-13. These are third-party analyst opinions — not CoinUnited’s view, not a price prediction, and not investment advice.

Scenario calculator

Pick a third-party reference level and see what it implies at leverage. Reference levels only - not a CoinUnited forecast.

Scenario price

$123.97

+0.0% vs current

Your margin (USD)Leverage

Position size $100,000.00

P&L at this scenario (long)

+$0.00

Loss if liquidated -$1,000.00 (the full margin)

Liquidation price (long): $122.73 — a move of -1.0%

Trade NUVL

Simplified: excludes fees, funding and slippage. Reference levels are third-party marks (CoinUnited daily kline; aggregated sell-side analyst targets), not forecasts. Leverage magnifies losses as much as gains - at high leverage a small adverse move liquidates the position. Not investment advice.

Catalysts & news

Dated third-party developments · newest first

Catalyst Timeline

Dated third-party developments that move the stock — newest first, each classified bullish or bearish and linked to its source.

2026-10-28
Next quarterly earnings◆ Scheduled
Next scheduled quarterly earnings report (2026-10-28). Revenue, margins and guidance are the near-term driver; the outcome is not known in advance.
Finnhub
2026-06-09
GSK acquires Nuvalent for $10.6 billion▲ Bullish
LONDON, June 9 (Reuters) - GSK (GSK.L) has agreed to buy U.S.-listed cancer drug developer Nuvalent (NUVL.O) for $10.6 billion in its largest deal in more than a decade, marking a strategic shift under new CEO ‌Luke Miels as the British…
Reuters
2026-06-09
Nuvalent shares surge 39% on GSK deal▲ Bullish
**GSK, Nuvalent** — Shares of Nuvalent, a U.S. pharmaceutical firm, surged nearly 39% following the announcement that GSK, a biopharmaceutical company based in the U.K., will acquire it for $10.6 billion.
CNBC
2026-06-09
GSK buying Nuvalent to rebuild oncology▲ Bullish
GSK Plc agreed to buy Nuvalent Inc. for $10.6 billion, securing a US biotech firm developing treatments for lung cancer as part of the British pharmaceutical company’s effort to rebuild its oncology franchise.
Bloomberg
2026-06-09
GSK tender offer $124 per share▲ Bullish
GSK said it would launch a tender offer of $124 a share in cash for Nuvalent. ...
The Wall Street Journal

Machine-readable table — same developments, with source

Recent third-party developments classified bullish / bearish for the stock; verbatim, sourced.

Date	Development	Direction	Source
2026-10-28	Next scheduled quarterly earnings report (2026-10-28). Revenue, margins and guidance are the near-term driver; the outcome is not known in advance.	◆ Scheduled	Finnhub
2026-06-09	LONDON, June 9 (Reuters) - GSK (GSK.L) has agreed to buy U.S.-listed cancer drug developer Nuvalent (NUVL.O) for $10.6 billion in its largest deal in more than a decade, marking a strategic shift under new CEO ‌Luke Miels as the British…	▲ Bullish	Reuters
2026-06-09	GSK, Nuvalent — Shares of Nuvalent, a U.S. pharmaceutical firm, surged nearly 39% following the announcement that GSK, a biopharmaceutical company based in the U.K., will acquire it for $10.6 billion.	▲ Bullish	CNBC
2026-06-09	GSK Plc agreed to buy Nuvalent Inc. for $10.6 billion, securing a US biotech firm developing treatments for lung cancer as part of the British pharmaceutical company’s effort to rebuild its oncology franchise.	▲ Bullish	Bloomberg
2026-06-09	GSK said it would launch a tender offer of $124 a share in cash for Nuvalent. ...	▲ Bullish	The Wall Street Journal

Основные выводы

•The $10.6B GSK acquisition at $124/share has effectively capped near-term equity upside, converting NUVL from a pure biotech growth story into a merger-arbitrage instrument — the dominant trading thesis is now deal closure probability, not pipeline valuation.
•Nuvalent's two lead assets (neladalkib for ALK+ NSCLC and zidesamtinib for ROS1+ NSCLC) have both generated positive pivotal trial data with NDAs submitted and 2026 PDUFA dates pending, meaning the underlying clinical value that attracted GSK is substantiated — a deal break would reset valuation toward these fundamentals.
•Forecast revenue and EPS growth of approximately 55.9% and 58.5% per year respectively far outpace the broader U.S. market, but Nuvalent is expected to remain unprofitable over the next three years — making the company strategically valuable to a large acquirer like GSK while limiting its standalone near-term earnings appeal.
•Short interest of 7.61% of outstanding shares reflects a meaningful contingent of traders positioning for deal friction or break risk, creating asymmetric volatility potential around key regulatory and antitrust milestones.
•Morningstar's fair value estimate of approximately $93 per share (implying the stock now trades at a significant premium to their standalone DCF) underscores that current prices are supported entirely by the acquisition premium — in a break scenario, NUVL could reprice dramatically toward intrinsic oncology pipeline value.

Ownership

Top institutional holders (SEC Form 13F)

Top Institutional Holders

SEC 13F

The largest institutional shareholders, from SEC Form 13F filings — who holds the stock and how much.

Institution	Shares	Value
Deerfield Management Company, L.P.	17.2M	$1.8B
FMR LLC	9.3M	$950.2M
Paradigm Biocapital Advisors LP	5.3M	$545.5M
BlackRock, Inc.	4.8M	$494.3M
JPMorgan Chase & Co.	3.1M	$298.7M
RA Capital Management, L.P.	2.5M	$259.6M
Vanguard Portfolio Management LLC	2.5M	$256.2M
Wellington Management Group LLP	2.5M	$253.1M
Vanguard Capital Management LLC	2.4M	$248.8M
State Street Corp.	2.0M	$208.6M

Source: SEC Form 13F filings · 263 institutional holders · as of 31-MAR-2026. 13F data is quarterly and lagged (filed ~45 days after quarter-end) and covers US institutional managers (>$100M AUM) only — not insiders, retail, or foreign holders. Not investment advice.

Understand the risks

Read before trading

Trading Risks

An honest, up-front list of the risks — both out of respect for the trader and as a YMYL compliance requirement.

Leverage / Liquidation

High leverage means a small adverse move can trigger forced liquidation and loss of your full margin.

High-valuation volatility

A high P/E stock is very sensitive to interest-rate and narrative shifts; swings can be large.

Session gaps

After-hours and weekend gaps; extended-hours liquidity is thinner than the regular session.

Basis risk

The CFD reference price can diverge from the exchange execution price.

Earnings volatility

Price swings widen around earnings dates and other scheduled disclosures.

Regulatory / event

Recalls, policy changes, or company-specific events can cause sharp moves.

Reference

FAQ & glossary

Часто задаваемые вопросы

GlaxoSmithKline agreed to acquire Nuvalent for approximately $10.6 billion, or $124 per share in cash, a deal that effectively re-rated NUVL from a speculative clinical-stage biotech into a merger-arbitrage situation. The acquisition is now the dominant driver of NUVL's share price, which trades very close to the agreed take-out price as of mid-2026. The deal is subject to standard closing conditions, including regulatory and antitrust review. No specific closing date has been publicly confirmed, but the market narrative through mid-June 2026 centers on deal completion timing rather than standalone pipeline valuation. The gap between NUVL's current trading price and the $124 offer price represents the merger-arbitrage spread — essentially the market's implied probability of deal closure and the time-cost of waiting for it.

Глоссарий

Ключевые термины по акциям и CFD, по одной строке на каждый, чтобы страница была однозначной и для читателей, и для ИИ-поисковиков.

CFD на акции	Контракт на разницу цен акции: только ценовая экспозиция, без владения самими акциями.
Расширенные часы торгов	Торги до открытия и после закрытия, вне основной сессии биржи.
Базисный риск	Риск того, что референсная цена CFD и цена исполнения на бирже перестанут двигаться синхронно.
P/E	Отношение цены к прибыли = цена акции / прибыль на акцию; распространённый показатель оценки.
Валовая маржа	Валовая прибыль / выручка; отражает рентабельность на уровне продукта.
Прибыль на акцию	Прибыль на акцию = чистая прибыль / разводнённое число акций в обращении.

символ

NUVL

Рынки

Акции

Код продукта CU

NUVL

Source Map

Every figure on this page traces to a primary or named third-party source. "As of" dates the source; "last checked" dates our most recent read of it.

Every figure here is also published as machine-readable data, and re-checked on a schedule so a stale one shows up as stale. View the raw data

Field	Value	Source	As of	Last checked
Reference price	live	CoinUnited stock CFD reference (live)	—	—	—
52-week range	$116.58 – $189.75	CoinUnited daily kline	—	2026-09-13	—
Next earnings	2026-10-28	Finnhub	—	2026-09-13	—
Institutional ownership	10 top holders	SEC Form 13F	31-MAR-2026	2026-09-13	View
Analyst price targets	$127.32 consensus	Aggregated sell-side analyst consensus	2026-09-13	2026-09-13	—
Peer valuations	6 peers	Third-party ratios (FMP), trailing twelve months	2026-09-13	2026-09-13	—
Founded	2017	Wikidata	—	2026-09-13	—
CoinUnited product	Stock CFD — price exposure, not equity (no voting; dividends reflected as adjustment); leverage available	CoinUnited product terms	—	2026-09-13	—

О авторе

CoinUnited.io Research Team

This Nuvalent, Inc. page is compiled by CoinUnited.io's research team: analysts covering listed equities and global markets, working from primary filings and named third-party data rather than opinion.

Наша методология исследования

Every figure is traced to a primary or named third-party source and dated: financial statements from the company’s SEC filings, institutional ownership from Form 13F, analyst targets from aggregated third-party coverage, and market data from the CoinUnited reference price. The Source Map on this page lists each one with its source and the date we last checked it.

Disclaimer: content is for informational and educational purposes only and is not personalized financial advice. A stock CFD carries significant risk and provides price exposure only, not equity ownership. Always conduct your own research and consult a qualified financial advisor.

Отказ от ответственности и ссылки

Важное предупреждение о рисках

A CoinUnited stock CFD gives price exposure to Nuvalent, Inc. only, not equity ownership: no shareholder voting rights, no dividends, and no settlement in the underlying share.

Leverage magnifies losses as well as gains, and a position can be liquidated long before the underlying share price recovers. The underlying listing trades on exchange hours, so the reference price can gap between sessions.

Пользователям рекомендуется проводить собственные исследования и консультироваться с квалифицированными финансовыми специалистами перед принятием инвестиционных решений. Создатели и операторы данной платформы не несут ответственности за любые финансовые убытки или иные ущербы, которые могут возникнуть в результате полагания на предоставленную информацию.

Leveraged trading is extremely risky and you may lose your entire deposit.

Обзор методологии

Figures on this page are compiled from primary and named third-party sources, not produced by a forecasting model. Each one carries its source and date in the Source Map above.

Financial statements: the company’s own SEC filings (10-K / 10-Q), read from XBRL
Market data: the CoinUnited reference price and daily closes
Institutional ownership: SEC Form 13F quarterly filings
Analyst targets: aggregated third-party sell-side coverage — third-party opinion, not CoinUnited’s view
Peer multiples: third-party trailing-twelve-month ratios

CoinUnited does not publish a price forecast or target for Nuvalent, Inc..

Последнее обновление методологии:

Готовы начать торговать Nuvalent, Inc.?

Присоединяйтесь к тысячам трейдеров и начните свое путешествие по торговле Nuvalent, Inc. сегодня. Получите доступ к продвинутым торговым инструментам и конкурентоспособным комиссиям.

Торговля NUVL/USDT Зарегистрируйтесь сейчас

NUVL

Nuvalent, Inc.

$123.97

▲+0.00%24h

24h Low24h High

$0.0000$0.0000

Bid

$123.69

Ask

$124.24

Trade Now

Up to 1000x leverage•Tiered fees

Live from CoinUnited.io

NUVL

$123.97+0.00%

Торгуйте сейчас

Перейти к другим криптовалютам

Быстрые ссылки

Калькулятор позиции

Nuvalent, Inc.

How to trade it

Статус торгового режима

How the NUVL CFD works

Trading conditions on CoinUnited

Trading NUVL CFDs on CoinUnited.io: Merger-Arb Strategy with Up to 1000x Leverage

Understanding the Merger-Arb Structure

Leverage Mechanics: A Worked Example

Key NUVL Catalyst Events to Track

Break-Scenario Risk and Short-Side Positioning

Position Sizing Summary

Готовы торговать NUVL?

Key facts & how to trade

Access & Tradability Comparison

Ключевые факты

Цена и рыночная структура

Company & financials

What Is Nuvalent, Inc. (NUVL)?

A Pipeline Built Around Two Validated Oncology Targets

From Development-Stage Biotech to M&A Instrument

Business Model and Strategic Rationale

Ключевые Инсайты

Why Trade NUVL? The Merger-Arbitrage and Break-Scenario Case

The Merger-Arbitrage Setup

The Break Scenario: Asymmetric Downside

Key Catalysts to Monitor

Framework for Assessing Risk-Reward

Valuation & peers

Peer Valuation Comparison

Analyst Price Targets

Targets by firm

Scenario calculator

Catalysts & news

Catalyst Timeline

Основные выводы

Ownership

Top Institutional Holders

Understand the risks

Trading Risks

Reference

Часто задаваемые вопросы

1. What is the GSK acquisition of Nuvalent (NUVL) and when is it expected to close?

2. What happens to NUVL stock if the GlaxoSmithKline acquisition deal breaks or falls through?

3. What are neladalkib and zidesamtinib, and why did they attract a $10.6 billion acquisition bid?

4. Is NUVL profitable and does it pay a dividend?

5. What is the current merger-arbitrage spread on NUVL and how do traders profit from it?

6. How does Nuvalent's ALK inhibitor neladalkib compare to Pfizer's lorlatinib for NSCLC?

7. What are the FDA PDUFA dates for Nuvalent's drug pipeline in 2026?

8. Why is trading NUVL as a CFD on CoinUnited different from buying the NYSE-listed shares?

9. How are dividends handled on the NUVL CFD at CoinUnited?

10. What does Nuvalent's P/E ratio tell investors, and why is it unusual?

11. How volatile is NUVL around clinical data readouts and regulatory announcements?

12. Can I trade NUVL CFDs on weekends or after the NYSE closes?

13. What is basis risk when trading NUVL as a CFD, and how does it arise?

14. How does leverage work for NUVL CFDs on CoinUnited, and what are the liquidation mechanics?

15. What short-selling mechanics apply to NUVL CFDs on CoinUnited?

16. Are there any eligibility or regulatory restrictions on trading NUVL CFDs depending on my country of residence?

17. How are NUVL CFD gains and losses typically treated for tax purposes?

18. What is Nuvalent's cash runway and why does it matter for NUVL CFD traders?

19. How does the zero-fee structure on CoinUnited affect the economics of holding a NUVL CFD position?

20. What institutional ownership and index inclusion dynamics should NUVL CFD traders be aware of?

Глоссарий

символ

Рынки

Код продукта CU

Source Map

О авторе

CoinUnited.io Research Team

Наша методология исследования

Отказ от ответственности и ссылки

Важное предупреждение о рисках

Обзор методологии

Готовы начать торговать Nuvalent, Inc.?

NUVL